Invention Grant
- Patent Title: Compounds
-
Application No.: US17901390Application Date: 2022-09-01
-
Publication No.: US11993595B2Publication Date: 2024-05-28
- Inventor: Alison Jones , Mark Ian Kemp , Martin Lee Stockley , Karl Richard Gibson , Gavin Alistair Whitlock , Andrew Madin
- Applicant: Mission Therapeutics Limited
- Applicant Address: GB Cambridge
- Assignee: Mission Therapeutics Limited
- Current Assignee: Mission Therapeutics Limited
- Current Assignee Address: GB Cambridge
- Priority: GB 16754 2014.09.23
- Main IPC: C07D417/12
- IPC: C07D417/12 ; C07D401/12 ; C07D401/14 ; C07D403/12 ; C07D405/14 ; C07D413/12 ; C07D413/14 ; C07D417/14 ; C07D471/04 ; C07D487/04 ; C07D513/04

Abstract:
The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.
Public/Granted literature
- US20230052191A1 NOVEL COMPOUNDS Public/Granted day:2023-02-16
Information query